47N0 Stock Chart & Stats
€3.29
€0.00(0.00%)
At close: 4:00 PM EST
€3.29
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.29 - €3.29
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€11.57M
Enterprise Value€23.90
Total Cash (Recent Filing)€4.59M
Total Debt (Recent Filing)€808.16K
Price to Earnings (P/E)―
Beta-1.33
Next Earnings
Aug 17, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding27,452,570
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.50Price Target Upside6.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€42.51M
Bulls Say, Bears Say
Bulls Say
Clinical Trials And DataMino-Lok demonstrated an improvement in treatment of CRBSI, achieving its primary endpoint in the P3 study.
Commercialization PotentialCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.
Regulatory ProgressThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.
Bears Say
Financial ConstraintsCitius Pharma reported a net loss with very limited cash, indicating the need to raise capital soon.
Financial PerformanceThe company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.
Regulatory DelaysCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.
Citius Pharmaceuticals News
47N0 FAQ
What was Citius Pharma’s price range in the past 12 months?
Citius Pharma lowest stock price was €3.29 and its highest was €3.29 in the past 12 months.
What is Citius Pharma’s market cap?
Citius Pharma’s market cap is €11.57M.
When is Citius Pharma’s upcoming earnings report date?
Citius Pharma’s upcoming earnings report date is Aug 17, 2026 which is in 26 days.
How were Citius Pharma’s earnings last quarter?
Citius Pharma released its earnings results on May 15, 2026. The company reported -€0.833 earnings per share for the quarter, missing the consensus estimate of -€0.246 by -€0.587.
Is Citius Pharma overvalued?
According to Wall Street analysts Citius Pharma’s price is currently Undervalued.
Does Citius Pharma pay dividends?
Citius Pharma does not currently pay dividends.
What is Citius Pharma’s EPS estimate?
Citius Pharma’s EPS estimate is -0.32.
How many shares outstanding does Citius Pharma have?
Citius Pharma has 27,452,570 shares outstanding.
What happened to Citius Pharma’s price movement after its last earnings report?
Citius Pharma reported an EPS of -€0.833 in its last earnings report, missing expectations of -€0.246. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Citius Pharma?
Currently, no hedge funds are holding shares in DE:47N0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Citius Pharma
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
47N0 Stock 12 Month Forecast
Average Price Target
€3.50
▲(6.27% Upside)